[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337673-105":59,"doc-detail-337673-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","eravacycline-an-antibacterial-drug-repurposed-for-pancreatic-cancer-therapy-case-study-insights-from-a-molecular-based-deep-learning-model","Eravacycline, an Antibacterial Drug, Repurposed for Pancreatic Cancer Therapy - Case Study - Insights From a Molecular-Based Deep Learning Model","","Pancreatic ductal adenocarcinoma (PDAC) is a major health threat with limited effective treatments, partly due to advanced diagnosis and inherent chemotherapy resistance. The study repurposes drugs with anti-cancer potential using machine learning, addressing the need for novel therapeutic strategies. A neural network is trained on drug–target interaction data enriched with drug–drug interaction information, then applied to eravacycline. Eravacycline suppresses BxPC-3 proliferation and migration and triggers apoptosis. Results support ML-based repurposing models for identifying candidate oncology agents.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/eravacycline-an-antibacterial-drug-repurposed-for-pancreatic-cancer-therapy-case-study-insights-from-a-molecular-based-deep-learning-model/337673/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/eravacycline-an-antibacterial-drug-repurposed-for-pancreatic-cancer-therapy-case-study-insights-from-a-molecular-based-deep-learning-model/337673.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is drug repurposing important for PDAC in this research?","Question",{"text":112,"@type":113},"PDAC has limited effective therapeutic options and strong resistance mechanisms. Repurposing FDA-approved drugs can reduce cost and risk while providing new anti-cancer candidates.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What machine learning approach does the study use?",{"text":117,"@type":113},"The study employs a neural network trained on drug–target interaction information enriched with drug–drug interaction information.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key experimental findings for eravacycline?",{"text":121,"@type":113},"Eravacycline significantly inhibited BxPC-3 cell proliferation and migration and induced apoptosis, supporting its potential anti-cancer activity in PDAC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337673,1790218381,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Briefings in Bioinformatics, 2024, 25(3), bbae108  \n[https://doi.org/10.1093/bib/bbae108](https://doi.org/10.1093/bib/bbae108)  \nCase Study  \nEravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: insights from a molecular-based deep learning model  \nAdi Jabarin†, Guy Shtar †, Valeria Feinshtein, Eyal Mazuz, Bracha Shapira, Shimon Ben-Shabat and Lior Rokach  \nCorresponding authors: Shimon Ben-Shabat, Ben-Gurion University of the Negev School of Pharmacy Department of Biochemistry & Pharmacology Faculty of Health Sciences POB 653, Beer-Sheva, 84105, Israel. Tel.: 972-8-6477363; Fax: 972-8-6479303; E-mail: [sbs@bgu.ac.il](sbs@bgu.ac.il); Lior Rokach, Software and Information Systems Engineering, Ben-Gurion University of the Negev P. O.B. 653, Beer-Sheva, 8410501, Israel. Tel.: +97286479338; Fax: +97286477527; E-mail: [liorrk@post.bgu.ac.il](liorrk@post.bgu.ac.il)[ ](liorrk@post.bgu.ac.il)†Adi Jabarin and Guy Shtar have contributed equally to this work and share the first authorship.  \nAbstract  \nBackground: Pancreatic ductal adenocarcinoma (PDAC) remains a serious threat to health, with limited effective therapeutic options, especially due to advanced stage at diagnosis and its inherent resistance to chemotherapy, making it one of the leading causes of cancerrelated deaths worldwide. The lack of clear treatment directions underscores the urgent need for innovative approaches to address and manage this deadly condition. In this research, we repurpose drugs with potential anti-cancer activity using machine learning (ML) . Methods: We tackle the problem by using a neural network trained on drug–target interaction information enriched with drug–drug interaction information, which has not been used for anti-cancer drug repurposing before. We focus on eravacycline, an antibacterial drug, which was selected and evaluated to assess its anti-cancer effects.  \nResults: Eravacycline significantly inhibited the proliferation and migration of BxPC-3 cells and induced apoptosis.  \nConclusion: Our study highlights the potential of drug repurposing for cancer treatment using ML. Eravacycline showed promising results in inhibiting cancer cell proliferation, migration and inducing apoptosis in PDAC. These findings demonstrate that our developed ML drug repurposing models can be applied to a wide range of new oncology therapeutics, to identify potential anti-cancer agents. This highlights the potential and presents a promising approach for identifying new therapeutic options.  \nKeywords: pancreatic ductal adenocarcinoma; machine learning; drug repurposing; eravacycline  \nINTRODUCTION  \nWith minimal treatment options, pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. This cancer is recognized as one of the deadliest malignancies, and it is the leading cause of cancer-related deaths in Western countries [1 , 2] . The presence of multiple changes in signaling pathways may partially explain some of this cancer’s resistance mechanisms [3] . Pancreatic cancer patients’ survival rate is estimated to average 5 years at most [4] . Chemotherapy, radiation and surgery are widely used but do not result in significant improvements in clinical outcomes [5] . The absence of effective treatment options underscores the urgency for new approaches to treat and manage this deadly disease.  \nRepurposing drugs that have already been approved by the Food and Drug Administration (FDA) for other indications has become a widely accepted approach for discovering new anticancer drugs, reducing costs and eliminating the need for toxicological tests. An existing drug may have a higher success rate thana potential drug in the FDA’s new chemical entity track [6] . A deep learning approach for identifying and predicting new indications for existing drugs was extended to other areas [7–9] . In the case of pancreatic cancer, where the mechanisms of the disease remain unclear, this approach may be extremely valuable. Drug reuse for PDAC has re","cbCaiqga3LFn95lc","https://ap.wps.com/l/cbCaiqga3LFn95lc","pdf",1258891,"English","# Abstract\n# Introduction\n# Keywords","[{\"question\":\"Why is drug repurposing important for PDAC in this research?\",\"answer\":\"PDAC has limited effective therapeutic options and strong resistance mechanisms. Repurposing FDA-approved drugs can reduce cost and risk while providing new anti-cancer candidates.\"},{\"question\":\"What machine learning approach does the study use?\",\"answer\":\"The study employs a neural network trained on drug–target interaction information enriched with drug–drug interaction information.\"},{\"question\":\"What were the key experimental findings for eravacycline?\",\"answer\":\"Eravacycline significantly inhibited BxPC-3 cell proliferation and migration and induced apoptosis, supporting its potential anti-cancer activity in PDAC.\"}]","Eravacycline, an Antibacterial Drug, Repurposed for Pancreatic Cancer Therapy - Case Study - Insights From a Molecular-Based Deep Learning Model | PDF",1790020070,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2d6a0de84b1c69d5707d8c5f73bb6cc.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f0987413bd0a1cc506e75da0b7fb6e9.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79c0aa28f4c28c8171356c1d50f2db35.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16ac3ad91add36db8f04e546bb7c2ff6.webp",980,1287]